Octapharma announces that the final results from the phase III ProDERM study will be presented at the American College of Rheumatology (ACR) Convergence 2020 virtual ... Nov 07
The development of inhibitors against exogenous FVIII can reduce the effectiveness of treatment and negatively impact a patient's long-term joint health and quality ... Oct 20
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, in addition to more ... Feb 17
Octapharma demonstrates commitment to improving haemophilia, a treatment at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)... Feb 08
Octapharma announced today that the European Medicines Agency has authorised an updated Summary of Product Characteristics (SmPC) for Nuwiq® that includes information on personalised prophylaxis ... Oct 01
-Advertisements-
.jpeg)
Tuesday, January 21, 2025
.jpeg){kind=logo}
